BR112021019287A2 - Uso de folistatina, método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano, e folistatina para uso como um biomarcador - Google Patents

Uso de folistatina, método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano, e folistatina para uso como um biomarcador

Info

Publication number
BR112021019287A2
BR112021019287A2 BR112021019287A BR112021019287A BR112021019287A2 BR 112021019287 A2 BR112021019287 A2 BR 112021019287A2 BR 112021019287 A BR112021019287 A BR 112021019287A BR 112021019287 A BR112021019287 A BR 112021019287A BR 112021019287 A2 BR112021019287 A2 BR 112021019287A2
Authority
BR
Brazil
Prior art keywords
follistatin
biomarker
diabetes
type
composing
Prior art date
Application number
BR112021019287A
Other languages
English (en)
Inventor
De Marinis Yang
Original Assignee
Lundoch Diagnostics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundoch Diagnostics AB filed Critical Lundoch Diagnostics AB
Publication of BR112021019287A2 publication Critical patent/BR112021019287A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Library & Information Science (AREA)
  • Endocrinology (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)

Abstract

uso de folistatina, método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano, e folistatina para uso como um biomarcador. trata-se do uso de folistatina como um biomarcador para o diagnóstico e/ou a previsão precoces de diabetes tipo 2, secreção de folistatina hepática regulada por gckr, tal uso é relatado no presente documento. ademais, um método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano é revelado no presente documento.
BR112021019287A 2019-03-28 2020-03-30 Uso de folistatina, método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano, e folistatina para uso como um biomarcador BR112021019287A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950381 2019-03-28
PCT/EP2020/058971 WO2020193808A1 (en) 2019-03-28 2020-03-30 Use of follistatin in type 2 diabetes risk prediction

Publications (1)

Publication Number Publication Date
BR112021019287A2 true BR112021019287A2 (pt) 2022-02-01

Family

ID=70058386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019287A BR112021019287A2 (pt) 2019-03-28 2020-03-30 Uso de folistatina, método para compor uma assinatura de biomarcador para a previsão precoce de diabetes tipo 2 em um ser humano, e folistatina para uso como um biomarcador

Country Status (13)

Country Link
US (1) US20220252615A1 (pt)
EP (1) EP3948294B1 (pt)
JP (1) JP2022526227A (pt)
KR (1) KR20210144809A (pt)
CN (1) CN114026426A (pt)
AU (1) AU2020245775A1 (pt)
BR (1) BR112021019287A2 (pt)
CA (1) CA3134929A1 (pt)
EA (1) EA202192466A1 (pt)
ES (1) ES2954164T3 (pt)
MX (1) MX2021011807A (pt)
PL (1) PL3948294T3 (pt)
WO (1) WO2020193808A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
US20070026458A1 (en) * 2004-12-17 2007-02-01 Entelos, Inc. Assessing insulin resistance using biomarkers
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2010057135A2 (en) * 2008-11-14 2010-05-20 The Regents Of The University Of California Methods and compositions for predicting a subject's susceptibility to and risk of developing type 2 diabetes
SG10201502531SA (en) * 2009-10-19 2015-05-28 Theranos Inc Integrated Health Data Capture And Analysis System

Also Published As

Publication number Publication date
MX2021011807A (es) 2021-10-26
PL3948294T3 (pl) 2023-10-16
WO2020193808A1 (en) 2020-10-01
JP2022526227A (ja) 2022-05-24
US20220252615A1 (en) 2022-08-11
CA3134929A1 (en) 2020-10-01
CN114026426A (zh) 2022-02-08
EP3948294B1 (en) 2023-06-07
EP3948294A1 (en) 2022-02-09
EA202192466A1 (ru) 2022-02-16
KR20210144809A (ko) 2021-11-30
ES2954164T3 (es) 2023-11-20
AU2020245775A1 (en) 2021-09-23
EP3948294C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
CO2020009625A2 (es) Inhibidor de fap
BR112018075288A2 (pt) métodos para diagnóstico de infecções bacterianas e virais
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112016028866A2 (pt) dispositivos para vedação de grampos em tecidos
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112016009099A2 (pt) Método para determinar se um indivíduo de teste tendo um distúrbio metabólico é um candidato para o tratamento com uma variante de fgf19, método para determinar se uma variante de fgf19 é um candidato para tratar um indivíduo de teste, uso de uma variante fgf19, modelo para determinar se uma variante de fgf19 é um candidato para prevenir uma doença
BR112017012874A2 (pt) disposições de acionamento para instrumentos cirúrgicos articuláveis
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
BR112016017041A2 (pt) Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
BR112022007677A2 (pt) L-asparaginase recombinante
BR112016021621A2 (pt) unidade de teste para análise quantitativa de um padrão de contato em uma superfície dentada de uma engrenagem, método para análise quantitativa e uso da unidade de teste
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
CL2018002645A1 (es) Sulfonamidas sustituidas para controlar plagas animales
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
BR112017014419A2 (pt) diagnose e tratamento de diabetes incipiente
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
ECSP19077969A (es) Compuesto heterociclico
BRPI0917656A2 (pt) Fatores viii e ix humanos produzidos de forma recombinante
BR112017019841A2 (pt) técnica de análise de amostra de tecido
BR112018012160A2 (pt) composição, métodos para preparar uma composição de negro de fumo e para preparar um composto de borracha, e, composto de borracha.
BR112014026063A2 (pt) equipamento de imagens, método, e equipamento do método

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]